- $278.59m
- $134.77m
- 44
- 23
- 73
- 44
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.98 | ||
| Price to Tang. Book | 1.98 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -40.63% | ||
| Return on Equity | -54.98% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue and skeleton. The Company is also focused on developing a novel therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-Binding Cassette in the C6 family (ABCC6) Deficiencies. The Company’s lead product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to cleave extracellular adenosine triphosphate (ATP) to generate plasma pyrophosphate (PPi) and adenosine monophosphate (AMP), which can be processed to phosphate and adenosine. Its INZ-701 is in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency and calciphylaxis.
Directors
- Douglas Treco NEC (63)
- Axel Bolte PRE (49)
- Stephen Dipalma CFO (62)
- Henric Bjarke COO (54)
- Steven Jungles SVP (55)
- Gayle Gironda SVP
- Deborah Wenkert SVP (62)
- Sarah Bhagat IND (35)
- Reinaldo Diaz IND (67)
- Martin Edwards IND (65)
- Robert Hopfner IND (49)
- Edward Mathers IND (61)
- Lynne Sullivan IND (55)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- September 11th, 2015
- Public Since
- July 24th, 2020
- No. of Shareholders
- 31
- No. of Employees
- 59
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 61,771,977
- Address
- 321 SUMMER STREET, SUITE 400, BOSTON, 02210
- Web
- https://www.inozyme.com/
- Phone
- +1 8573304340
- Auditors
- Ernst & Young LLP
Upcoming Events for INZY
Inozyme Pharma Inc Annual Shareholders Meeting
Q2 2024 Inozyme Pharma Inc Earnings Release
Similar to INZY
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Inozyme Pharma share price?
As of Today at 19:11 UTC, shares in Inozyme Pharma are trading at $4.51. This share price information is delayed by 15 minutes.
How has the Inozyme Pharma share price performed this year?
Shares in Inozyme Pharma last closed at $4.51 and the price had moved by -21.57% over the past 365 days. In terms of relative price strength the Inozyme Pharma share price has underperformed the S&P500 Index by -34.73% over the past year.
What are the analyst and broker recommendations for Inozyme Pharma?
The overall consensus recommendation for Inozyme Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Inozyme Pharma dividend yield?
Inozyme Pharma does not currently pay a dividend.
Does Inozyme Pharma pay a dividend?
Inozyme Pharma does not currently pay a dividend.
When does Inozyme Pharma next pay dividends?
Inozyme Pharma does not currently pay a dividend.
How do I buy Inozyme Pharma shares?
To buy shares in Inozyme Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Inozyme Pharma?
As of the previous close price of $4.51, shares in Inozyme Pharma had a market capitalisation of $278.59m.
Where are Inozyme Pharma shares listed?
Here are the trading details for Inozyme Pharma:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: INZY
What kind of share is Inozyme Pharma?
Based on an overall assessment of its quality, value and momentum Inozyme Pharma is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Inozyme Pharma share price forecast for 2024?
The analyst consensus target price for shares in Inozyme Pharma is $20.33. That is 350.78% above the last closing price of $4.51.
Analysts covering Inozyme Pharma currently have a consensus Earnings Per Share (EPS) forecast of -$1.50 for the next financial year.
What is the trend in the Inozyme Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Inozyme Pharma. Over the past six months, its share price has outperformed the S&P500 Index by +32.95%.
As of the last closing price of $4.51, shares in Inozyme Pharma were trading -5.33% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Inozyme Pharma PE Ratio?
The Inozyme Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $4.51.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Inozyme Pharma?
Inozyme Pharma's management team is headed by:
- Douglas Treco - NEC
- Axel Bolte - PRE
- Stephen Dipalma - CFO
- Henric Bjarke - COO
- Steven Jungles - SVP
- Gayle Gironda - SVP
- Deborah Wenkert - SVP
- Sarah Bhagat - IND
- Reinaldo Diaz - IND
- Martin Edwards - IND
- Robert Hopfner - IND
- Edward Mathers - IND
- Lynne Sullivan - IND